3SBio Files to Begin Trial of Anemia Drug

3SBio Inc. applied to the SFDA to begin a registrational clinical trial for Feraheme™ (ferumoxytol) Injection, an IV treatment for iron deficiency anemia in patients with chronic kidney disease. 3SBio licensed the China rights for the drug from AMAG Pharmaceuticals last May, shortly before AMAG was granted approval for the product by the US FDA. More details... Stock Symbols: (NSDQ: SSRX) (NSDQ: AMAG)